Takeda Pharmaceutical Company L (TAK) Stock Price & How to Invest
Last updated July 2026
Short answer
TAK is the NYSE-listed ADR of Takeda Pharmaceutical, Japan's largest drugmaker, and it trades as a transition story: a high dividend yield and cheap forward earnings multiple set against the erosion of past blockbusters (Vyvanse, and Entyvio later this decade) that new launches must replace.
TAK stock price
As of 2026-07-24, Takeda Pharmaceutical Company L (TAK) last closed at $17.24, up 19.1% over the past year. Over the past 52 weeks it has traded between $13.23 and $18.80.
Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or Takeda Pharmaceutical Company L's investor relations page. Walnut is informational, not investment advice.
What does Takeda Pharmaceutical Company L (TAK) do?
Takeda Pharmaceutical is Japan's largest pharmaceutical company and a top-tier global drugmaker, with roughly JPY 4.5 trillion (around $28 billion) in annual revenue concentrated in gastroenterology (Entyvio for inflammatory bowel disease), rare diseases, plasma-derived therapies, oncology, neuroscience, and vaccines. The company scaled up dramatically through its 2019 acquisition of Shire, which added rare-disease and plasma assets but also loaded the balance sheet with debt that management has been steadily paying down. Takeda trades in the US as an ADR under the ticker TAK while its primary listing is on the Tokyo Stock Exchange (4502).
The investment picture is defined by a patent-cliff transition. Vyvanse, a former blockbuster ADHD drug, has lost US exclusivity and generics have sharply cut its revenue, and Takeda's largest product, the IBD drug Entyvio, faces biosimilar competition later this decade. To offset this, management is leaning on cost discipline, a subcutaneous version of Entyvio, and a late-stage pipeline led by oveporexton (TAK-861), an oral orexin agonist for narcolepsy that received FDA Priority Review in early 2026. The stock offers a mid-single-digit dividend yield and a low forward earnings multiple, reflecting both the defensive cash flows and the market's skepticism about near-term growth.
What's driving Takeda Pharmaceutical Company L (TAK)?
1. Oveporexton and the late-stage pipeline
Oveporexton (TAK-861), a first-in-class oral orexin receptor 2 agonist for narcolepsy type 1, met all endpoints in two pivotal Phase 3 studies and won FDA Priority Review in February 2026. Takeda is positioning it plus five other late-stage programs (spanning narcolepsy, psoriasis, and polycythemia) as the core of growth from the late 2020s onward. Commercial success here is the single biggest swing factor for the equity.
2. Entyvio defense and subcutaneous conversion
Entyvio for inflammatory bowel disease is Takeda's largest product and a key cash generator, but core patents expire around 2028 in the US and 2027 in Europe. Management is pushing a subcutaneous formulation and pediatric indications to extend and defend the franchise ahead of biosimilar entry. How much revenue survives that transition shapes the medium-term earnings base.
3. Cost discipline and deleveraging
With revenue roughly flat as Vyvanse rolls off, Takeda has protected core operating profit largely through operating-expense savings while continuing to pay down the debt taken on for the Shire deal. Progress on the debt goal supports the dividend and gives the company flexibility, but it also constrains large-scale business development.
4. Income profile and yen exposure
Takeda pays a substantial dividend, yielding roughly 3.7 percent, which anchors the total-return case for a slow-growth pharma. Because the ADR reflects yen-denominated earnings, US investors also carry currency translation risk, and a stronger or weaker yen can meaningfully move reported ADR returns independent of the underlying business.
What are the risks to Takeda Pharmaceutical Company L (TAK)?
The central risk is that pipeline launches, above all oveporexton, do not ramp quickly enough to replace the revenue lost from Vyvanse generics and, later, Entyvio biosimilars, leaving earnings and the dividend under pressure. Regulatory or clinical setbacks on any late-stage asset would remove a key growth pillar. The company still carries meaningful post-Shire debt, and drug pricing pressure in the US and elsewhere weighs on the whole sector. For US holders, the ADR adds yen currency risk on top of company-specific execution risk, and reported statutory profit has been volatile due to impairments and one-time items.
How is Takeda Pharmaceutical Company L (TAK) valued? (approximate, July 2026)
A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Takeda Pharmaceutical Company L's investor relations page or your broker.
- Revenue (TTM): ~$28B (JPY ~4.5T)
- Market cap: ~$55B
- Share price (ADR): ~$17
- Forward P/E: ~6x
- Dividend yield: ~3.7%
- Revenue growth (YoY): ~-2%
Takeda's fiscal 2025 (ended March 2026) revenue slipped modestly as Vyvanse generic erosion outweighed newer growth products, while core operating profit held roughly flat thanks to cost savings. The low forward earnings multiple and mid-single-digit dividend yield reflect a market pricing in slow growth and patent-cliff risk rather than expansion. Statutory (GAAP-style) earnings have been noisy because of amortization and impairments tied to past acquisitions, so investors often focus on the company's core (adjusted) profit measures.
Who competes with Takeda Pharmaceutical Company L (TAK)?
Global big pharma peers
Large diversified drugmakers such as Pfizer, Novartis, AstraZeneca, and GSK compete with Takeda for capital, pipeline talent, and business-development assets, and set the valuation benchmark for a mature dividend-paying pharma.
Inflammatory bowel disease and immunology rivals
In Entyvio's core IBD market, Takeda faces AbbVie (Skyrizi, Rinvoq) and Johnson & Johnson (Stelara/Tremfya), plus a growing wave of vedolizumab biosimilar developers preparing for patent expiry later this decade.
Rare disease and plasma / neuroscience specialists
Takeda's rare-disease, plasma-derived therapy, and neuroscience franchises compete with players like CSL Behring, Sanofi, and specialty biotechs, including other companies pursuing orexin-based narcolepsy treatments.
How to invest in Takeda Pharmaceutical Company L (TAK)
There are three common ways to get TAK exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic basket, so TAK sits alongside other stocks that express the same thesis.
Walnut takes the basket route. Describe a thesis where TAK fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.
New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.
The bottom line on Takeda Pharmaceutical Company L (TAK)
Takeda is a mature, dividend-paying global pharma whose investment case hinges on whether its late-stage pipeline can outrun the loss of exclusivity on its legacy franchises.
More on Takeda Pharmaceutical Company L (TAK)
Whether TAK is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is TAK a buy?, and where the stock could go from here in the TAK stock forecast.
For income investors, whether TAK pays a dividend and how the payout looks is covered in does TAK pay a dividend?
Build a basket around TAK with Walnut
Use Takeda Pharmaceutical Company L as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
What is TAK stock?
+
TAK is the New York Stock Exchange-listed American Depositary Receipt (ADR) of Takeda Pharmaceutical Company, Japan's largest pharmaceutical firm. Each ADR represents an interest in Takeda's Tokyo-listed shares (ticker 4502), letting US investors hold the company in dollars.
What does Takeda do?
+
Takeda develops and sells prescription medicines globally, focused on gastroenterology (notably Entyvio for inflammatory bowel disease), rare diseases, plasma-derived therapies, oncology, neuroscience, and vaccines. It generates around $28 billion in annual revenue across those areas.
Does TAK pay a dividend?
+
Yes. Takeda pays a semiannual dividend that translates to a yield of roughly 3.7 percent on the ADR as of mid-2026. Because earnings are yen-denominated, the dollar value US holders receive can vary with the yen exchange rate.
Why is Takeda's revenue declining?
+
The main driver is the loss of US patent exclusivity on Vyvanse, a former blockbuster ADHD drug, which let generics take share. New growth and launch products have only partly offset that decline, leaving overall revenue roughly flat to slightly down.
What is the patent cliff facing Takeda?
+
Vyvanse has already lost exclusivity, and Takeda's largest product, Entyvio, faces biosimilar competition as core patents expire around 2027 in Europe and 2028 in the US. Replacing that revenue with new launches is the central challenge for the business.
What is oveporexton (TAK-861)?
+
Oveporexton is Takeda's investigational oral orexin receptor 2 agonist for narcolepsy type 1. It met all endpoints in two Phase 3 studies and received FDA Priority Review in February 2026, making it a potential first-in-class launch and a key pipeline hope.
Is TAK cheap based on its valuation?
+
TAK trades at a low forward price-to-earnings multiple (around 6x) with a mid-single-digit dividend yield, which looks inexpensive versus peers. That reflects the market pricing in patent-cliff risk and slow growth rather than an obvious mispricing, so the low multiple carries real uncertainty.
What are the main risks of holding TAK?
+
Key risks include pipeline launches failing to offset Vyvanse and Entyvio revenue losses, clinical or regulatory setbacks, post-Shire debt, sector-wide drug pricing pressure, and yen currency risk on the ADR. Walnut is not an investment adviser, so weigh these against your own goals and research.
Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Takeda Pharmaceutical Company L's investor relations page or your broker before making investment decisions.